Table 4.
Clinical characteristics, follow-up, and outcomes of EXT1/EXT2-positive and EXT1/EXT2-negative LMN, with and without LN (combined class 5 LMN with or without class 3/4 LN)
| Variable | EXT1/EXT2-Positive LMN, n=64/122 (52.5%) | EXT1/EXT2-Negative LMN, n=96/252 (38.1%) | P Valuea |
|---|---|---|---|
| Age at presentation, median (IQR), yr | 33 (25–42) | 38 (28–47) | 0.10 |
| Female, n (%) | 57 (89.1) | 75 (78.1) | 0.07 |
| SCr at presentation, median (IQR), mg/dl | 0.80 (0.60–1.00), n=61 | 0.90 (0.70–1.40), n=89 | 0.004 |
| Proteinuria at presentation, median (IQR), g/24 h | 3.9 (1.6–6.7) n=53 | 3.0 (1.5–4.9), n=76 | 0.3 |
| Proteinuria at presentation ≥3.5/d, n (%) | 32 (60.4), n=53 | 33 (43.4), n=76 | 0.06 |
| Hematuria, n (%) | 19 (29.7) | 35 (36.5) | 0.38 |
| Proliferative features, n (%) | 16 (25.0) | 31 (32.3) | 0.32 |
| Other autoimmune diseases, n (%) | 19 (29.7) | 22 (22.9) | 0.34 |
| Sclerosed glomeruli, median (IQR), % | 0.0 (0.0–10.2) | 13.2 (1.82–25.0) | <0.001 |
| IFTA, median (IQR), % | 0.0 (0.0–0.0) | 10.0 (5.0–20.0) | <0.001 |
| SCr at end of follow-up, median (IQR), mg/dl | 0.90 (0.70–1.20), n=51 | 1.10 (0.70–1.60), n=71 | 0.05 |
| Proteinuria at end of follow-up, median (IQR), g/24 h | 0.85 (0.20–2.00), n=36 | 0.90 (0.25–2.35), n=57 | 0.89 |
| Proteinuria at end of follow-up ≥3.5/d, n (%) | 3 (8.3), n=36 | 9 (15.8), n=57 | 0.3 |
| ESKD, n (%) | 2 (3.1) | 18 (18.8) | 0.003 |
| Death, n (%) | 2 (3.1) | 8 (8.3) | 0.18 |
| Time of follow-up, median (IQR), mo | 48.6 (33.1–76.5) | 50.6 (32.7–86.8) | 0.85 |
a
P<0.05 is considered significant.